1. High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics.

    Clinical Infectious Diseases 61(4):593 (2015) PMID 25904368

    Multidrug-resistant Enterobacteriaceae (MRE) are widespread in the community, especially in tropical regions. Travelers are at risk of acquiring MRE in these regions, but the precise extent of the problem is not known. From February 2012 to April 2013, travelers attending 6 international vaccina...
  2. Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.

    The Journal of clinical pharmacology and new drugs 55(1):10 (2015) PMID 25042595

    During antibiotic treatments, active residuals reaching the colon profoundly affect the bacterial flora resulting in the emergence of resistance. To prevent these effects, we developed an enteric-coated formulated activated-charcoal based product, DAV132, meant to deliver its adsorbent to the il...
  3. Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: A proof of concept study in healthy subjects.

    The Journal of clinical pharmacology and new drugs 55(1):10 (2015) PMID 25042595

    During antibiotic treatments, active residuals reaching the colon profoundly affect the bacterial flora resulting in the emergence of resistance. To prevent these effects, we developed an enteric-coated formulated activated-charcoal based product, DAV132, meant to deliver its adsorbent to the il...
  4. Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.

    The Journal of clinical pharmacology and new drugs 55(1):10 (2015) PMID 25042595

    During antibiotic treatments, active residuals reaching the colon profoundly affect the bacterial flora resulting in the emergence of resistance. To prevent these effects, we developed an enteric-coated formulated activated-charcoal based product, DAV132, meant to deliver its adsorbent to the il...
  5. Prolonged hospital stay, an adverse effect of strict national policy for controlling the spread of highly resistant microorganisms.

    Infection Control and Hospital Epidemiology 35(11):1427 (2014) PMID 25333442

  6. Prolonged hospital stay, an adverse effect of strict national policy for controlling the spread of highly resistant microorganisms.

    Infection Control and Hospital Epidemiology 35(11):1427 (2014) PMID 25333442

  7. Prolonged hospital stay, an adverse effect of strict national policy for controlling the spread of highly resistant microorganisms.

    Infection Control and Hospital Epidemiology 35(11):1427 (2014) PMID 25333442

  8. Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted.

    PLoS computational biology 10(9):e1003840 (2014) PMID 25210849 PMCID PMC4161292

    Fecal excretion of antibiotics and resistant bacteria in the environment are major public health threats associated with extensive farming and modern medical care. Innovative strategies that can reduce the intestinal antibiotic concentrations during treatments are in development. However, the ef...
  9. Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted.

    PLoS computational biology 10(9):e1003840 (2014) PMID 25210849 PMCID PMC4161292

    Fecal excretion of antibiotics and resistant bacteria in the environment are major public health threats associated with extensive farming and modern medical care. Innovative strategies that can reduce the intestinal antibiotic concentrations during treatments are in development. However, the ef...
  10. Ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii.

    Scandinavian Journal of Infectious Diseases 46(3):215 (2014) PMID 24447250

    Risk factors for ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Gram-negative bacilli (CR-GNB) have rarely been evaluated in intensive care units (ICU) without epidemic carbapenemase-producing Acinetobacter baumannii or Enterobacteriaceae. We addressed this issue in a cohor...
  11. Ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii.

    Scandinavian Journal of Infectious Diseases 46(3):215 (2014) PMID 24447250

    Risk factors for ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Gram-negative bacilli (CR-GNB) have rarely been evaluated in intensive care units (ICU) without epidemic carbapenemase-producing Acinetobacter baumannii or Enterobacteriaceae. We addressed this issue in a cohor...
  12. Candida albicans is not always the preferential yeast colonizing humans: a study in Wayampi Amerindians.

    Journal of Infectious Diseases 208(10):1705 (2013) PMID 23904289

    In industrialized countries Candida albicans is considered the predominant commensal yeast of the human intestine, with approximately 40% prevalence in healthy adults. We discovered a highly original colonization pattern that challenges this current perception by studying in a 4- year interval a...
  13. Candida albicans is not always the preferential yeast colonizing humans: a study in Wayampi Amerindians.

    Journal of Infectious Diseases 208(10):1705 (2013) PMID 23904289

    In industrialized countries Candida albicans is considered the predominant commensal yeast of the human intestine, with approximately 40% prevalence in healthy adults. We discovered a highly original colonization pattern that challenges this current perception by studying in a 4- year interval a...
  14. Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.

    Antimicrobial Agents and Chemotherapy 57(11):5423 (2013) PMID 23959311 PMCID PMC3811274

    Antibiotics excreted into the intestinal tract, such as broad-spectrum cephalosporins, disrupt the indigenous microflora, affect colonization resistance (CR), and promote intestinal colonization by resistant bacteria. We tested whether oral DAV131, a charcoal-based adsorbent, would prevent colon...
  15. Lincosamide resistance mediated by lnu(C) (L phenotype) in a Streptococcus anginosus clinical isolate.

    Journal of Antimicrobial Chemotherapy 68(11):2464 (2013) PMID 23812683

    Unique resistance to lincosamides (L phenotype) due to the production of nucleotidyltransferases (Lnu) is uncommon among Gram-positive bacteria. The aim of the study was to characterize the L phenotype in a clinical isolate of the Streptococcus milleri group. The strain UCN93 was recovered from ...
  16. Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.

    Antimicrobial Agents and Chemotherapy 57(11):5423 (2013) PMID 23959311 PMCID PMC3811274

    Antibiotics excreted into the intestinal tract, such as broad-spectrum cephalosporins, disrupt the indigenous microflora, affect colonization resistance (CR), and promote intestinal colonization by resistant bacteria. We tested whether oral DAV131, a charcoal-based adsorbent, would prevent colon...
  17. Lincosamide resistance mediated by lnu(C) (L phenotype) in a Streptococcus anginosus clinical isolate.

    Journal of Antimicrobial Chemotherapy 68(11):2464 (2013) PMID 23812683

    Unique resistance to lincosamides (L phenotype) due to the production of nucleotidyltransferases (Lnu) is uncommon among Gram-positive bacteria. The aim of the study was to characterize the L phenotype in a clinical isolate of the Streptococcus milleri group. The strain UCN93 was recovered from ...
  18. Decolonization of intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial.

    Journal of Antimicrobial Chemotherapy 68(10):2375 (2013) PMID 23719234

    Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are an increasingly frequent cause of infections in the community and the healthcare setting. In this study, we aimed to investigate whether intestinal carriage of ESBL-E can be eradicated. We conducted a double-blind, randomize...
  19. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

    Clinical Microbiology Reviews 26(4):744 (2013) PMID 24092853 PMCID PMC3811232

    In the last 10 years, extended-spectrum β-lactamase-producing enterobacteria (ESBL-E) have become one of the main challenges for antibiotic treatment of enterobacterial infections, largely because of the current CTX-M enzyme pandemic. However, most studies have focused on hospitalized patients, ...
  20. Extensively resistant VIM-2-positivePseudomonas aeruginosa

    The Lancet Infectious Diseases 13(10):828 (2013)